Abstract
Role of clonoSEQ®, a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have